Abstract 1664P
Background
Despite important implications for patient outcomes, psycho-oncology care (POC) remains underappreciated in low-middle income countries like India. Screening in our patient population revealed high distress levels, among both patients/caregivers and emphasized barriers in accessing mental health care. Our study tests a model of care which proposes early integration of POC in a clinical cancer care setting.
Methods
A multidisciplinary team of ten healthcare professionals, including oncologists, psychologists, oncology nurses and social workers, developed the proposed model. The key components and interventions were: (1) linking counsellor consultation with first patient registration (2) co-counselling of patients and caregivers pre, during and post treatment (3) accessibility of psychologists in inpatient departments through joint ward rounds with treating clinician.
Results
Between Dec 2023 to Mar 2024, 1674 patients reported to Radiation Oncology OPD and 265 had inpatient admissions. The implementation of this model resulted in 31.9% increase in psychological counsellor consultations for outpatients (5.4% to 37.3%), and 82.6% increase for inpatients (12.2% to 94.8%). It also showed 62.68% increase in co-counselling (16.6% to 79.46%). Counsellors flagged off important issues like fear of recurrence or infertility, intimacy issues and reluctance to continuing therapy which patients were hesitant in sharing with the treating physician. Patient reported satisfaction levels evaluated using the OUT-PATSAT35 questionnaire also increased from 62% to 75%.
Conclusions
This model highlights simple ways to prioritise accessibility to mental healthcare in resource limited settings, without adding to the physician work burden and resulting in positive patient outcomes. Increased counsellor accessibility could also be attributed to employing more manpower (3 counsellors versus 1 prior to the study). Despite advising counselling at first contact, not all patients reported for it highlighting a significant barrier to mental therapy. Longer follow up is warranted to evaluate this model’s effectiveness and sustainability.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
N.Bisht.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1709P - Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study
Presenter: Deepak Kilari
Session: Poster session 11
1710P - Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study
Presenter: Benoit Blanchet
Session: Poster session 11
1711P - Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?
Presenter: John McGrane
Session: Poster session 11
1712P - Real-world efficacy of first-line nivolumab plus ipilimumab and its practical predictive biomarkers in advanced renal cell carcinoma: First analysis from RENOIR study [KCSG GU22-13]
Presenter: Jwa Hoon Kim
Session: Poster session 11
1713P - A deep learning approach utilizing the electronic health record (EHR) to identify cancer recurrence in renal cell carcinoma (RCC)
Presenter: Jue Hou
Session: Poster session 11
1714P - Detection and monitoring of translocation renal cell carcinoma via epigenomic profiling of cell-free DNA
Presenter: Simon Garinet
Session: Poster session 11
1715P - Interim analysis results from a phase II study of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma
Presenter: Xu Zhang
Session: Poster session 11
1716P - Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)
Presenter: martina catalano
Session: Poster session 11